Do Ozempic and Wegovy reduce inflammation as well as support weight loss in Europe?

Ozempic and Wegovy explained: semaglutide, GLP-1 receptor agonists, weight reduction, inflammatory markers (CRP), metabolic health, and prescribing criteria.

In this episode, we examine emerging research on semaglutide’s potential anti-inflammatory effects and how doctors interpret these findings under EU medical guidance.

You’ll learn:

• How GLP-1 receptor agonists improve glucose regulation and reduce appetite

• Why weight loss itself can lower systemic inflammation

• The role of C-reactive protein (CRP) as an inflammatory marker

• Current evidence on cardiovascular risk reduction

• The difference between approved indications and ongoing research

• Common side effects: nausea, vomi ...